

DIALOG(R) File 347:JAPIO

'(c) 2006 JPO & JAPIO. All rts. reserv.

04210158

SOLID PHARMACEUTICAL PREPARATION

PUB. NO.: 05-201858 [JP 5201858 A]
PUBLISHED: August 10, 1993 (19930810)
INVENTOR(s): MOROI MASAMI
NAKAJIMA YOICHI
IMAMORI KATSUMI
IWASA AKIRA
APPLICANT(s): SS PHARMACEUT CO LTD [358627] (A Japanese Company or
Corporation), JP (Japan)
APPL. NO.: 04-014193 [JP 9214193]
FILED: January 29, 1992 (19920129)
INTL CLASS: [5] A61K-031/135; A61K-031/135; A61K-031/375; A61K-047/12
JAPIO CLASS: 14.4 (ORGANIC CHEMISTRY -- Medicine)
JOURNAL: Section: C, Section No. 1134, Vol. 17, No. 644, Pg. 24,
November 30, 1993 (19931130)

ABSTRACT

PURPOSE: To provide a stable solid pharmaceutical preparation causing no discoloration, containing, as active ingredients, ascorbic acid (salt), ephedrine-type alkaloid, and organic acid.

CONSTITUTION: The objective solid pharmaceutical preparation containing, as active ingredients, (A) 0.5-50wt.% of ascorbic acid or its salt, (B) 0.1-10wt.% of an ephedrine-type alkaloid (e.g. ephedrine hydrochloride), and (C) 0.5-50wt.% of an organic acid selected from dibasic acids and oxy acids (e.g. succinic acid). This pharmaceutical preparation can be obtained by formulating the above active ingredients with, according to the purpose, as the case may be, antipyretic/analgesic ingredient(s), anti-histamine ingredient, antitussive ingredient, expectorant ingredient, caffeine(s), vitamin(s), crude drug, or excipient, into tablets, granules, powder(s) through conventional process. So far, formulation of both ascorbic acid and ephedrine-type alkaloid has caused pharmaceutical preparation's discoloration, leading to a drawback of impairing such preparation's commodity value; however, it has been found that a specific organic acid has discoloration-preventive activity.